Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol

<strong>Introduction</strong> Catheter-related sepsis is one of the most dangerous complications of neonatal intensive care and is associated with significant morbidity and mortality. Use of catheter-care ‘bundles’ has reduced the incidence of catheter-related sepsis, although individual...

Descrición completa

Detalles Bibliográficos
Main Authors: Clarke, P, Craig, J, Wain, J, Tremlett, C, Linsell, L, Bowler, U, Juszczak, E, Heath, P
Formato: Journal article
Publicado: BMJ Publishing Group 2019
_version_ 1826265484353339392
author Clarke, P
Craig, J
Wain, J
Tremlett, C
Linsell, L
Bowler, U
Juszczak, E
Heath, P
author_facet Clarke, P
Craig, J
Wain, J
Tremlett, C
Linsell, L
Bowler, U
Juszczak, E
Heath, P
author_sort Clarke, P
collection OXFORD
description <strong>Introduction</strong> Catheter-related sepsis is one of the most dangerous complications of neonatal intensive care and is associated with significant morbidity and mortality. Use of catheter-care ‘bundles’ has reduced the incidence of catheter-related sepsis, although individual components have not been well studied. Better evidence is needed to guide selection of the most appropriate antiseptic solution for skin disinfection in preterm neonates. This study will inform the feasibility and design of the first randomised controlled trial to examine the safety and efficacy of alcohol-based versus aqueous-based chlorhexidine antiseptic formulations for skin disinfection prior to percutaneous central venous catheterisation in preterm neonates. The antiseptics to be compared are 2% chlorhexidine gluconate (CHG) aqueous and 2% CHG in 70% isopropyl alcohol. <strong>Methods and analysis</strong> The Antiseptic Randomised Controlled Trial for Insertion of Catheters (ARCTIC) is a two-centre randomised-controlled feasibility trial. At least 100 preterm infants born at &lt;34 weeks’ gestation and due to undergo percutaneous insertion of a central venous catheter will be randomly allocated to receive prior skin disinfection with one of the two antiseptic solutions. Outcomes include: i) recruitment and retention rates; ii) completeness of data collection; iii) numbers of enrolled infants meeting case definitions for definite catheter-related sepsis, catheter-associated sepsis and catheter colonisation and iv) safety outcomes of skin morbidity scores recorded daily from catheter insertion until 48 hours post removal. The key feasibility metrics will be reported as proportions with 95% CIs. Estimated prevalence of catheter colonisation will allow calculation of sample size for the large-scale trial. The data will inform whether it will be feasible to progress to a large-scale trial. <strong>Ethics and dissemination</strong> ARCTIC has been approved by the National Health Service Health Research Authority National Research Ethics Service Committee East of England (Cambridge South) (IRAS ID 163868), was adopted onto the National Institute of Health Research Clinical Research Network portfolio (CPMS ID 19899) and is registered with an International Standard Randomised Control Trials Number (ISRCTN: 82571474; Pre-results) and European Clinical Trials Database number 2015-000874-36. Dissemination plans include presentations at scientific conferences, scientific publications and sharing of the findings with parents via the support of Bliss baby charity.
first_indexed 2024-03-06T20:24:25Z
format Journal article
id oxford-uuid:2eebcdfb-ed2c-4458-aaea-c848b5223d38
institution University of Oxford
last_indexed 2024-03-06T20:24:25Z
publishDate 2019
publisher BMJ Publishing Group
record_format dspace
spelling oxford-uuid:2eebcdfb-ed2c-4458-aaea-c848b5223d382022-03-26T12:52:02ZSafety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocolJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2eebcdfb-ed2c-4458-aaea-c848b5223d38Symplectic Elements at OxfordBMJ Publishing Group2019Clarke, PCraig, JWain, JTremlett, CLinsell, LBowler, UJuszczak, EHeath, P<strong>Introduction</strong> Catheter-related sepsis is one of the most dangerous complications of neonatal intensive care and is associated with significant morbidity and mortality. Use of catheter-care ‘bundles’ has reduced the incidence of catheter-related sepsis, although individual components have not been well studied. Better evidence is needed to guide selection of the most appropriate antiseptic solution for skin disinfection in preterm neonates. This study will inform the feasibility and design of the first randomised controlled trial to examine the safety and efficacy of alcohol-based versus aqueous-based chlorhexidine antiseptic formulations for skin disinfection prior to percutaneous central venous catheterisation in preterm neonates. The antiseptics to be compared are 2% chlorhexidine gluconate (CHG) aqueous and 2% CHG in 70% isopropyl alcohol. <strong>Methods and analysis</strong> The Antiseptic Randomised Controlled Trial for Insertion of Catheters (ARCTIC) is a two-centre randomised-controlled feasibility trial. At least 100 preterm infants born at &lt;34 weeks’ gestation and due to undergo percutaneous insertion of a central venous catheter will be randomly allocated to receive prior skin disinfection with one of the two antiseptic solutions. Outcomes include: i) recruitment and retention rates; ii) completeness of data collection; iii) numbers of enrolled infants meeting case definitions for definite catheter-related sepsis, catheter-associated sepsis and catheter colonisation and iv) safety outcomes of skin morbidity scores recorded daily from catheter insertion until 48 hours post removal. The key feasibility metrics will be reported as proportions with 95% CIs. Estimated prevalence of catheter colonisation will allow calculation of sample size for the large-scale trial. The data will inform whether it will be feasible to progress to a large-scale trial. <strong>Ethics and dissemination</strong> ARCTIC has been approved by the National Health Service Health Research Authority National Research Ethics Service Committee East of England (Cambridge South) (IRAS ID 163868), was adopted onto the National Institute of Health Research Clinical Research Network portfolio (CPMS ID 19899) and is registered with an International Standard Randomised Control Trials Number (ISRCTN: 82571474; Pre-results) and European Clinical Trials Database number 2015-000874-36. Dissemination plans include presentations at scientific conferences, scientific publications and sharing of the findings with parents via the support of Bliss baby charity.
spellingShingle Clarke, P
Craig, J
Wain, J
Tremlett, C
Linsell, L
Bowler, U
Juszczak, E
Heath, P
Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol
title Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol
title_full Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol
title_fullStr Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol
title_full_unstemmed Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol
title_short Safety and efficacy of 2% chlorhexidine gluconate aqueous versus 2% chlorhexidine gluconate in 70% isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates: the ARCTIC randomised-controlled feasibility trial protocol
title_sort safety and efficacy of 2 chlorhexidine gluconate aqueous versus 2 chlorhexidine gluconate in 70 isopropyl alcohol for skin disinfection prior to percutaneous central venous catheter insertion in preterm neonates the arctic randomised controlled feasibility trial protocol
work_keys_str_mv AT clarkep safetyandefficacyof2chlorhexidinegluconateaqueousversus2chlorhexidinegluconatein70isopropylalcoholforskindisinfectionpriortopercutaneouscentralvenouscatheterinsertioninpretermneonatesthearcticrandomisedcontrolledfeasibilitytrialprotocol
AT craigj safetyandefficacyof2chlorhexidinegluconateaqueousversus2chlorhexidinegluconatein70isopropylalcoholforskindisinfectionpriortopercutaneouscentralvenouscatheterinsertioninpretermneonatesthearcticrandomisedcontrolledfeasibilitytrialprotocol
AT wainj safetyandefficacyof2chlorhexidinegluconateaqueousversus2chlorhexidinegluconatein70isopropylalcoholforskindisinfectionpriortopercutaneouscentralvenouscatheterinsertioninpretermneonatesthearcticrandomisedcontrolledfeasibilitytrialprotocol
AT tremlettc safetyandefficacyof2chlorhexidinegluconateaqueousversus2chlorhexidinegluconatein70isopropylalcoholforskindisinfectionpriortopercutaneouscentralvenouscatheterinsertioninpretermneonatesthearcticrandomisedcontrolledfeasibilitytrialprotocol
AT linselll safetyandefficacyof2chlorhexidinegluconateaqueousversus2chlorhexidinegluconatein70isopropylalcoholforskindisinfectionpriortopercutaneouscentralvenouscatheterinsertioninpretermneonatesthearcticrandomisedcontrolledfeasibilitytrialprotocol
AT bowleru safetyandefficacyof2chlorhexidinegluconateaqueousversus2chlorhexidinegluconatein70isopropylalcoholforskindisinfectionpriortopercutaneouscentralvenouscatheterinsertioninpretermneonatesthearcticrandomisedcontrolledfeasibilitytrialprotocol
AT juszczake safetyandefficacyof2chlorhexidinegluconateaqueousversus2chlorhexidinegluconatein70isopropylalcoholforskindisinfectionpriortopercutaneouscentralvenouscatheterinsertioninpretermneonatesthearcticrandomisedcontrolledfeasibilitytrialprotocol
AT heathp safetyandefficacyof2chlorhexidinegluconateaqueousversus2chlorhexidinegluconatein70isopropylalcoholforskindisinfectionpriortopercutaneouscentralvenouscatheterinsertioninpretermneonatesthearcticrandomisedcontrolledfeasibilitytrialprotocol